Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has proved helpful vigilantly but unsuccessfully to develop a single therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is actually an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set out what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such a highly marketing image in the Uptick Newswire interview that I came away with a poor opinion of the business.

Irony of irony, the bad impression of mine of the business has grown steadily, however, the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of this know-how as well as linked intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) as well as the first brand new drug application approval ($5 million), and even royalty payments of five % of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple therapies and numerous indications, it’s this individual therapies as well as a “broad pipeline of indications” as it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an energetic company with diverse interests albeit centered on leronlimab, several disease sorts, multiple publications and multiple presentations.

Might all this be smoke and mirrors? That is a question I’ve been asking myself from the very start of the interest of mine in this particular organization. Judging by the multiples of thousands of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *